




FIG. 1




FIG. 2B




FIG. 2A

3/42






FIG. 3

4/42



5/42




FIG. 5

6/42




FIG. 6

7/42




FIG. 7

8/42




FIG. 8

9/42




FIG. 9

10/42




FIG. 10A

11/42




FIG. 10B

TEST AGENT	ROUTE	SCHEDULE	DOSE (mg/kg)	DAY 0 (n)	LAST DAY	LAST DAY (n)	DAY 18 (VOLUME)	%TGI (LOWER, UPPER)	TTP 2X	PR	CR
MCT + MDV3100 VEHICLE	PO/PO	QD + QD	0	9	21	8	935	0 (0, 0)	11	0	0
GDC-0068	PO	QD	50	9	21	9	553	54 (19, 82)	NA	0	0
MDV3100	PO	QD	5	9	21	9	596	43 (0, 72)	17.5	0	0
EXAMPLE 2 + MDV3100	PO/PO	QD + QD	50 + 5	9	21	8	309	95 (73, 115)	NA	0	0

FIG. 10C

13/42




FIG. 11A




FIG. 11B

14/42




FIG. 11C




FIG. 11D

15/42

COMBO CI VALUE SUMMARY

CELL LINE	TUMOR TYPE	GENE MUTATIONS	CHEMOTHERAPEUTIC	CHEMO EC50	GDC-0068 EC50	SYNERGY?	GDC-0068 CI EC50
BT549	BREAST	PTEN NEG, K-RAS	5-FU	>40	>2.5	NO	0.83
CAL-51	BREAST	P13K E542K, PTEN NEG	5-FU	>40	0.29	YES	0.6
CAL-51X1.1	BREAST		5-FU	8	0.6	YES	0.65
CAL120	BREAST		5-FU	>40	>2.5	YES	0.61
HCC1954	BREAST	P13K H1047R	5-FU	>40	0.9	NO	0.7
MDA-MB-361	BREAST	P13K E545K	5-FU	>40	>2.5	YES	0.27
MCF7	BREAST	P13K E545K	5-FU	7.8	>2.5	YES	0.5
MCF7(PRC)	BREAST		5-FU	7.8	>2.5	YES	0.34
MDA-MB468	BREAST	P13K C789G T435I, PTEN NEG	5-FU	20	>2.5	NO	1.24
ZR-75-1	BREAST	PTEN NEG	5-FU	20	>2.5	YES	0.37
U87(PRC)	GLIOMA		5-FU	12	>2.5	YES	0.3
H2122	LUNG	KRAS G12C	5-FU	0.35	>2.5	NO	0.85
KPPI	MOUSE LINE		5-FU	0.9	>2.5	YES?	0.67??
IGROV1	OVARIAN	P13K O1069W	5-FU	15.6	0.66	YES	0.56
22RV1	PROSTATE	P13K Q546R, B-RAF L597R	5-FU	0.625	>2.5	NO	1.05
PC3(GNE)	PROSTATE	PTEN NEG, P13K N986H	5-FU	>40	2.2	NO	0.84
MCF7(PRC)	BREAST		CARBOPLATIN	>12.5	>2.5	YES	0.49
MDA-MB-361	BREAST	P13K E545K	CARBOPLATIN	>12.5	>2.5	YES	0.19
U87(PRC)	GLIOMA		CARBOPLATIN	>12.5	>2.5	NO	0.72

TO FIG. 12B

FIG. 12A

16/42

FROM FIG. 12A

A549(GNE)	LUNG	PI3K M772X N996H, KRAS G12S	CARBOPLATIN	>12.5	>2.5	YES	0.51
A549(PRC)	LUNG		CARBOPLATIN	>12.5	>2.5	YES	0.66
H1299(PRC)	LUNG		CARBOPLATIN	>12.5	>2.5	NO	0.77
H2122	LUNG	KRAS G12C	CARBOPLATIN	>12.5	>2.5	NO	0.87
A375(PRC)	MELANOMA	(B-RAF V600E IN GNE LINE)	CARBOPLATIN	>12.5	>2.5	NO	0.84
IGROV1	OVARIAN	PI3K Q1069W	CARBOPLATIN	>12.5	0.56	NO	1.2
SKOV3(PRC)	OVARIAN		CARBOPLATIN	>12.5	>2.5	NO	1.09
PC3(GNE)	PROSTATE	PTEN NEG, PI3K N996H	CARBOPLATIN	>12.5	>2.5	YES	0.69
PC3(PRC)	PROSTATE		CARBOPLATIN	>12.5	>2.5	NO	0.95
KM12	COLON	PTEN NEG	CPT-11	>2.5	>2.5	YES	0.57
WDR	COLON		CPT-11	>2.5	>2.5	YES	0.54
BT549	BREAST	PTEN NEG, K-RAS	DOCETAXEL	0.002	>2.5	YES	0.47
CAL-51	BREAST	PI3K E542K, PTEN NEG	DOCETAXEL	0.003	0.29	YES	0.54
CAL-51X1.1	BREAST		DOCETAXEL	0.009	0.6	YES	0.58
CAL120	BREAST		DOCETAXEL	0.02	>2.5	YES	0.4
HCC1954	BREAST	PI3K H1047R	DOCETAXEL	0.004	0.9	YES	0.48
MCF7	BREAST	PI3K E548K	DOCETAXEL	0.005	>2.5	YES	0.43
MCF7(PRC)	BREAST		DOCETAXEL	0.005	>2.5	YES	0.47
MDA-MB-361	BREAST	PI3K E548K	DOCETAXEL	0.003	>2.5	YES	0.24
MDA-MB468	BREAST	PI3K C769G T435I, PTEN NEG	DOCETAXEL	0.005	>2.5	NO	0.78

TO FIG. 12C

FIG. 12B

17/42

FROM FIG. 12B

ZR-75-1	BREAST	PTEN NEG	DOCETAXEL	0.0025	>2.5	YES	0.52
U87 (ARRAY)	GLIOMA		DOCETAXEL	0.0025	>2.5	YES	0.17
U87 (ARRAY)	GLIOMA		DOCETAXEL	0.009	>2.5	YES	0.2
U87 (GNE)	GLIOMA	P13K I397M, PTEN NEG	DOCETAXEL	0.00625	>2.5	YES	0.47
U87 (GNE)	GLIOMA	P13K I397M, PTEN NEG	DOCETAXEL	0.009	>2.5	YES	0.35
U87 (PRC)	GLIOMA		DOCETAXEL	0.009	>2.5	YES	0.32
U87 (PRC)	GLIOMA		DOCETAXEL	0.00625	>2.5	YES	0.42
U87 (PRC)	GLIOMA		DOCETAXEL	0.009	>2.5	YES	0.25
A549 (GNE)	LUNG	P13K M772X N996H, KRAS G12S	DOCETAXEL	0.0025	>2.5	YES	0.59
A549 (PRC)	LUNG		DOCETAXEL	0.0025	>2.5	YES	0.39
H1299 (PRC)	LUNG		DOCETAXEL	0.025	>2.5	NO	0.72
H2122	LUNG	- KRAS G12C	DOCETAXEL	0.01	>2.5	NO/YES?	0.71(0.54)
A375 (PRC)	MELANOMA		DOCETAXEL	0.0025	>2.5	YES	0.64
IGROV1	OVARIAN	P13K Q1069W	DOCETAXEL	0.00392	0.56	YES	0.54
SKOV3 (PRC)	OVARIAN		DOCETAXEL	0.005	>2.5	NO	0.79
22RV1	PROSTATE	P13K Q546R, B-RAF L597R	DOCETAXEL	0.005	>2.5	YES	0.64
PC3 (GNE)	PROSTATE	PTEN NEG, P13K N996H	DOCETAXEL	0.0062	1.09	YES	0.44(0.66)
PC3 (PRC)	PROSTATE		DOCETAXEL	0.0025	>2.5	YES	0.55
MCF7 (PRC)	BREAST		DOXORUBICIN	0.2	>2.5	YES	0.35
U87 (PRC)	GLIOMA		DOXORUBICIN	0.15	>2.5	NO	0.92

TO FIG. 12D

FIG. 12C

18/42

FROM FIG. 12C

A549(GNE)	LUNG	PI3K M772X N996H, KRAS G12S	DOXORUBICIN	0.2	>2.5	YES	0.48
A549(PRC)	LUNG		DOXORUBICIN	0.2	>2.5	YES	0.67
H1299(PRC)	LUNG		DOXORUBICIN	0.2	>2.5	NO	0.8
H2122	LUNG	KRAS G12C	DOXORUBICIN	0.01	>2.5	NO	0.9
A375(PRC)	MELANOMA		DOXORUBICIN	0.03	>2.5	NO	0.72
EO21	OVARIAN	PTEN NEG, B-RAF V457N	DOXORUBICIN	0.12	0.3	NO	0.91
SKOV3	OVARIAN	PI3K H1047R	DOXORUBICIN	0.3	>2.5	YES	0.67
SKOV3(PRC)	OVARIAN		DOXORUBICIN	0.07	>2.5	NO	0.87
PC3(GNE)	PROSTATE	PTEN NEG, PI3K N996H	DOXORUBICIN	0.4	>2.5	NO	0.74
PC3(PRC)	PROSTATE		DOXORUBICIN	0.4	>2.5	YES	0.38
BT549	BREAST	PTEN NEG, K-RAS	GEMCITABINE	0.012	>2.5	NO	0.73
CAL-51	BREAST	PI3K E542K, PTEN NEG	GEMCITABINE	0.0024	0.29	NO	0.87
CAL-51X1.1	BREAST		GEMCITABINE	0.00625	0.6	YES	0.47
CAL120	BREAST		GEMCITABINE	0.7	>2.5	YES	0.12
HCC1954	BREAST		GEMCITABINE	0.005	0.9	YES	0.61
MCF7	BREAST	PI3K H1047R	GEMCITABINE	0.005	>2.5	YES	0.42
MCF7(PRC)	BREAST	PI3K E545K	GEMCITABINE	0.00625	>2.5	YES	0.44
MDA-MB-361	BREAST	PI3K E545K	GEMCITABINE	0.012	>2.5	YES	0.19
MDA-MB468	BREAST	PI3K C769G T435I, PTEN NEG	GEMCITABINE	0.0025	>2.5	NO	1.14

TO FIG. 12E

FIG. 12D

19/42

FROM FIG. 12D

ZR75-1	BREAST	PTEN NEG	GEMCITABINE	0.01	>2.5	YES	0.42
U87(PRC)	GLIOMA		GEMCITABINE	0.00625	>2.5	YES	0.3
A549(GNE)	LUNG	PI3K M772X N996H, KRAS G12S	GEMCITABINE	0.01	>2.5	YES	0.38
A549(PRC)	LUNG		GEMCITABINE	0.01	>2.5	YES	0.35
H2122	LUNG	KRAS G12C	GEMCITABINE	0.0027	>2.5	NO	0.7
KPP1	MOUSE LINE		GEMCITABINE	0.017	>2.5	NO	1.04
IGROV1	OVARIAN	PI3K O1069W	GEMCITABINE	0.0088	0.66	NO	0.92
SKOV3	OVARIAN	PI3K H1047R	GEMCITABINE	0.05	>2.5	NO	0.97
22RV1	PROSTATE	PI3K Q546R, B-RAF L597R	GEMCITABINE	0.005	>2.5	YES	0.54
PC3(GNE)	PROSTATE	PTEN NEG, PI3K N996H	GEMCITABINE	0.125	>2.5	YES	0.67
PC3(PRC)	PROSTATE		GEMCITABINE	0.0125	>2.5	YES	0.34
COLO205	COLON	B-RAF V600E	SN38	0.012	>2.5	YES	0.55
HCT116	COLON	PI3K H1047R	SN38	0.024	>2.5	YES	0.48
HT29	COLON	B-RAF V600E	SN38	0.04	>2.5	NO	0.93
G40	GLIOMA	PTEN NEG	TEMODAR	>10	>2.5	NO	0.73
G61	GLIOMA		TEMODAR	>10	>2.5	YES	0.55
U87(GNE)	GLIOMA	PI3K I397M, PTEN NEG	TEMODAR	>10	>2.5	YES	0.31
LOX	MELANOMA	B-RAF V600E	TEMODAR	>10	>2.5	NO	0.93

FIG. 12E




FIG. 13A




FIG. 13B




FIG. 14




FIG. 15A




FIG. 15B




FIG. 16A




FIG. 16B

27/42




FIG. 17A

28/42




FIG. 17B

29/42




FIG. 18A

30/42




FIG. 18B

31/42




FIG. 19

32/42




FIG. 20

33/42

PATIENT	TUMOR	PI3K MUT	PTEN H-SCORE	STUDY TIME	BEST RESP	PET+ LESION	SUV MAX				%Δ CYC 1	%Δ CYC 2	%Δ CYC 3
							SCREEN	CYCLE 1	CYCLE 2	CYCLE 3			
1	BREAST HR+ HER2-	H1047R	60	ONGOING CYCLE 7	SD	LT LUNG LIVER LIVER	5.1 11.2 10.5	4.1 10.9 10.4	1.6 3.1 4.4	5.1 9.4 9.4	-20 -3 -8	-69 -72 -58	0 -16 -10
2	BREAST HR+ HER2-	E545K	180	PD AFTER CYCLE 1	PD	LT LUNG LT LUNG LIVER LIVER	7.3 7.6 6.3 7.6	7.2 7.6 5.2 6.5			-1 0 -17 -14		
3	BREAST HR+ HER2-	WT	5	PD IN CYCLE 1		LIVER LIVER LADREN	11.4 5.6 9.5	12.1 3.6 3.1	13.1 4.2 9.2		+6 -36 -36	+15 -23 -3	
4	BREAST HR+ HER2-	WT	20	WITHDREW AFTER CYCLE 2	SD	R LUNG L LUNG	4.4 4.1	2.8 1.6	2.3 2.2		-36 -61	-48 -46	
5	BREAST HR+ HER2-	E110K	100	ONGOING CYCLE 3		LIVER LIVER	6.1 7.4	3.7 4.2	3.3 3.8		-39 -43	-46 -49	
6	BREAST	WT	240	ONGOING CYCLE 2		LIVER LIVER	4.8 4.0	1.5* 1.6*			-69* -60*		
7	BREAST		LOSS	CYCLE 1	PD								
8	BREAST		10	CYCLE 1	RASH								
9	BREAST		LOSS	CYCLE 1									
10	BREAST		LOSS	CYCLE 1									

FIG. 21

34/42




FIG. 22A

PATIENT 1

LESION ID	LESION LOCATION	SUV _{max}			% CHANGE RELATIVE TO SCR	
		SCR	C1 D22-28	C2 D15-21	C1 D22-28	C2 D15-21
401	LEFT LUNG	5.1	4.1	1.6	-21%	-69%
402	LIVER	11.2	10.9	3.1	-3%	-72%
403	LIVER	10.5	10.4	4.4	-1%	-58%
MEAN %CHANGE					-8%	-66%

FIG. 22B

35/42

LINE OF THERAPY	TREATMENT	TIME
FIRST	CYCLOPHOSPHAMIDE, ADRIAMYCIN, 5FU	6 MONTHS
SECOND	GEMCITABINE + CAPECITABINE	15 MONTHS
THIRD	FASLODEX	16 MONTHS
FOURTH	VINORELBINE + CAPECITABINE	21 MONTHS
FIFTH	PACLITAXEL	6 MONTHS
SIXTH	VINFLUNINE	7 MONTHS
SEVENTH	GDC-0068 600 mg	7 MONTHS AND ONGOING

FIG. 22C

TUMOR MARKERS		
DAY	CA15.3	CEA
-42	363	14.0
21	284	11.9
37	256	10.3
84	195	9.0
98	146	8.2

FIG. 22D

36/42




FIG. 23A

37/42

THERAPY	TREATMENT HISTORY	TIME
ADJUVANT	DOXORUBICIN + CYCLOPHOSPHAMIDE -> PACLITAXEL	4 MONTHS
METASTASIS	RESECTION OF BRAIN METASTASIS WITH RADIATION	2 MONTHS
FIRST - LINE	SINGLE - AGENT CAPECITABINE	7 MONTHS

FIG. 23B





FIG. 23C



LINE OF THERAPY	TREATMENT	TIME	BEST RESPONSE
DIAGNOSIS	RESECTION: SQUAMOUS CELL CARCINOMA OF CERVIX	MARCH 2009	
ADJUVANT	CISPLATIN + CONCOMITANT RADIATION	MARCH - MAY 2009	MIXED RESPONSE
FIRST - LINE	CARBOPLATIN AND PACLITAXEL x 6 CYCLES	NOV 2010 - MAY 2011	PR (RAPID PROGRESSION POST)
SECOND - LINE	GDC - 0068 + mFOLFOX - 6	SEPT 2011 - ONGOING	PR AT WEEK 8 (40% RECIST)

FIG. 24B

40/42




FIG. 25A

THERAPY	TREATMENT	TIME	BEST RESPONSE
ADJUVANT	FOLFOX - 4 x 12 CYCLES	6 MONTHS	
FIRST - LINE	IRINOTECAN + CETUXIMAB	4 MONTHS	SD
SECOND - LINE	PANITUMUMAB	17 MONTHS	PD
THIRD - LINE	GDC - 0068 + MFOLFOX - 6	6 MONTHS AND ONGOING	.40% PR AT WEEK 8 .50% cPR AT WEEK 12

FIG. 25B




FIG. 26